Get started
Live feed
·
PRReleasevia Quantisnow
Propanc Biopharma Inc. logo

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for PPCB

Across the 30 sessions after earlier PPCB headlines, the stock closed higher 12 times and lower 18 times, with a median move of 6.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

PPCB close-to-close change in the session after earlier headlines
SessionEarlier headlinePPCBSPY
Oct 16, 2026Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells+0.1%-1.1%
Oct 14, 2026Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer-11.3%-1.1%
Oct 7, 2026Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib+1.5%-0.2%
Sep 29, 2026Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results-4.0%-0.2%
Sep 22, 2026Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015+3.4%-0.0%
Sep 16, 2026Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.-22.6%-0.4%
Quantisnow market dataNASDAQ
Propanc Biopharma Inc. logo
PPCB
Propanc Biopharma Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Get push alerts for PPCB

Follow PPCB and get a push notification the moment its next story breaks.

Full PPCB profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PPCB (Propanc Biopharma Inc.) and more on Quantisnow.